UBS Maintains Neutral on RAPT Therapeutics, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Eliana Merle has maintained a Neutral rating on RAPT Therapeutics but significantly lowered the price target from $10 to $2.
September 09, 2024 | 2:23 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
UBS analyst Eliana Merle has maintained a Neutral rating on RAPT Therapeutics but significantly lowered the price target from $10 to $2.
The significant reduction in the price target from $10 to $2 by UBS suggests a negative outlook on RAPT's future performance. This is likely to lead to a decrease in investor confidence and a potential drop in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100